Tuberculosis not the only risk from new immunological drugs

May 20, 2008

A new survey cautions physicians that drugs commonly prescribed for patients suffering from immunological disorders such as rheumatoid arthritis and inflammatory bowel disease may carry risks of serious infections other than the known risk of tuberculosis. The survey published is in the June 1 issue of Clinical Infectious Diseases, currently available online.

As many as 50 million Americans may suffer from immunological disorders that are treated with drugs that suppress immunity. Among these drugs are agents that inhibit tumor necrosis factor-alpha (TNF), a cytokine receptor involved in cellular communication. It is known that anti-TNF therapies are associated with an increased risk of tuberculosis.

The new survey of infectious diseases physicians indicates that there is probably greater risk for other serious infections in these patients. Survey respondents reported 73 cases of Staphylococcus aureus, 56 cases of histoplasmosis, and 32 nontuberculosis mycobacterial infections among patients using these immune-modulating therapies, compared to 17 tuberculosis cases.

Kevin Winthrop, MD, of the Oregon Health and Sciences University, said: “While much attention has so far focused on tuberculosis cases occurring in patients using anti-TNF therapies, our findings suggest that nontuberculosus mycobacterial infections, histoplasmosis, and invasive S. aureus infections might all be occurring more frequently than TB in this setting within the United States.”

Patients are usually screened for tuberculosis prior to initiating anti-TNF therapy and this should continue, say the authors. However, clinicians should be vigilant not just for TB, but also for nontuberculosis mycobacterial infections in patients who are beginning or using these drugs, particularly those patients with underlying lung disease from rheumatoid arthritis, emphysema, or other conditions. In addition, clinicians should also be vigilant for mycobacterial infections in patients using rituximab (Rituxan), as a small number of the cases reported in this series occurred in patients using this B lymphocyte depletion therapy.

Source: Infectious Diseases Society of America

Explore further: Cuban doctor arrives in Switzerland for Ebola aid

add to favorites email to friend print save as pdf

Related Stories

Battling superbugs with gene-editing system

Sep 21, 2014

In recent years, new strains of bacteria have emerged that resist even the most powerful antibiotics. Each year, these superbugs, including drug-resistant forms of tuberculosis and staphylococcus, infect ...

Pocket diagnosis

Mar 19, 2014

A new app which turns any smartphone into a portable medical diagnostic device could help in the fight against diseases including HIV, tuberculosis and malaria in the developing world.

Recommended for you

Ebola death toll rises to 5,459: WHO

5 hours ago

The World Health Organization said Friday that 5,459 people had so far died of Ebola out of a total 15,351 cases of infection in eight countries since late December 2013.

Flu season off to a slow start ... for now

8 hours ago

(HealthDay)—This year's flu season is off to a slow but detectable start. And it appears to be a typical one that's likely to peak in January or February, a leading U.S. health official says.

Update on new treatments for liver diseases

9 hours ago

Cirrhosis and nonalcoholic fatty liver disease (NAFLD) are two serious liver conditions with limited pharmacological treatments. The December issues of AGA's journals—Clinical Gastroenterology and Hepatology and Gastro ...

Amateur photographers aid in remote skin sore trial

10 hours ago

Paediatric infectious disease specialists are bringing novel skin sore research methods to WA in the form of a protocol allowing non-professional photographers to capture high-quality images of skin sores ...

User comments : 0

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.